Cyrano Therapeutics Successfully Completes Enrollment for Phase 2 FLAVOR Trial of CYR-064 Targeting Smell Loss

Cyrano Therapeutics Completes Enrollment in Phase 2 FLAVOR Trial

Cyrano Therapeutics, Inc., a forward-thinking clinical-stage regenerative medicine company, has recently reached an important milestone by completing the enrollment of patients in its Phase 2 FLAVOR trial. This trial investigates the efficacy of their novel soft-mist nasal spray, CYR-064, designed to treat post-viral hyposmia, a condition characterized by reduced ability to smell following viral infections.

The FLAVOR trial is a randomized, double-blinded, placebo-controlled study that seeks to evaluate the safety, tolerability, and effectiveness of CYR-064 over a duration of six months. A total of 150 patients were enrolled across 14 clinical sites in the United States, a thorough effort to address a pressing medical issue affecting over 60 million individuals in the US, Europe, and Japan, and millions more worldwide.

Rick Geoffrion, President and CEO of Cyrano Therapeutics, expressed gratitude to both patients and investigators participating in this pivotal research. "Completion of enrollment in our FLAVOR trial marks a significant step in developing the first pharmaceutical treatment for post-viral smell loss," he stated. The company is now eagerly anticipating results from the trial, expected in the fourth quarter of 2025, which will direct the next steps in furthering CYR-064's development.

CYR-064 is notable for its patent-protected formulation that integrates a broad-spectrum phosphodiesterase (PDE) inhibitor intended to improve olfactory neuron responsiveness, thereby restoring the sense of smell. A groundbreaking aspect of its delivery system involves Ursatec's innovative 3K® pump technology paired with the Resyca soft mist spray method. This combination allows for accurate deposition of the medication directly into the olfactory region, ensuring that patients receive the treatment exactly where it's needed most.

The advantages of using a soft-mist formulation—characterized by controlled droplet size and minimized spray velocity—are substantial. This advanced delivery system is designed to maximize drug absorption, thereby potentially amplifying therapeutic effectiveness. By easing the administration process for patients, Cyrano Therapeutics increases the likelihood of positive outcomes during and after treatment.

Principal investigator Dr. Mas Takashima, a prominent figure in the field and Professor and Chairman of the Department of Otolaryngology at Houston Methodist Hospital, noted the importance of completing enrollment in the FLAVOR trial. "Our goal is to validate the promising potential of CYR-064, paving the way for the first evidence-based treatment for individuals combating post-viral hyposmia,” he commented. The commitment shown by participating patients has further energized the research team as they gear up to analyze the forthcoming results.

As a venture-backed private clinical-stage company, Cyrano Therapeutics has devoted its efforts to creating therapies for individuals dealing with the debilitating effects of smell and taste loss since its inception. As the medical community increasingly recognizes the implications of post-viral conditions such as hyposmia, the work of Cyrano Therapeutics may herald a new era of treatment options that could significantly enhance the quality of life for millions.

To discover more about Cyrano Therapeutics and their ongoing projects, you can visit their official website at cyranotherapeutics.com.

In conclusion, the completion of enrollment in the Phase 2 FLAVOR trial represents more than just a number of patients; it symbolizes hope for those impacted by sense loss and sets the stage for future breakthroughs in the treatment of post-viral conditions.